Investor Presentaiton
Innovent: Established Leadership in China with Unique Position
to Become a Global Premier Biopharmaceutical Company
Leading
2
1
biopharmaceutical
Core strategy of global
innovation
company in China
达伯舒
达攸同®
XX
苏立信
达伯华
利器昔单抗注射液
阿达木单抗注射液
Four commercialized products
•
Leading brand in China PD(L)-1
market; First included in NRDL
•
3,600+ total employees
•
Robust pipeline of 23 assets
across diversified clinical stages
Innovent
•
3
Fully-integrated,
multi-function
platform
Discovery
CMC
(manufacturing &
quality)
Commercialization
Development
Global R&D platform with
1,000+ talents in China, US and
Europe
Innovent Academy as a
powerful discovery engine to
nourish global FIC and BIC
Expand collaborations with
global partners
Confidential
Copyright©2021 Innovent Biologics
World-class discovery,
development, manufacturing
and commercialization
capabilities
24,000L current production
capacity with additional
36,000L to be completed,
one of the largest in China.
LO
5View entire presentation